Rena Emond

The paper develops a combination therapy for ER+ breast cancer that uses an evolutionary double-bind strategy to suppress drug resistance.

The paper shows that drug-sensitive breast cancer cells benefit from co-culture with resistant cells, which produce estradiol, leading to increased survival and resistance under treatment.

The paper shows that combining ribociclib and adavosertib reduces growth of mixed cancer cell cultures and limits resistance development.